Breast Cancer

Biotech company prepares to launch therapy for refractory breast cancer in the U.K.

Published in Cancer Weekly, October 8th, 2002

Biotechnology company Bioenvision is set to launch a major new weapon in the fight against breast cancer.

Modrenal is a refractory breast cancer treatment, which will be used in cases where front line treatment has failed to halt, or in some cases speeded up, the rate of cancer growth.

In clinical trials, Modrenal has proved 46% effective as a second line oncology treatment. The drug now has a U.K. license and should be available to U.K. cancer sufferers this year.

Modrenal harnesses new thinking on hormone sensitive cancers. Historically, scientists have worked on the theory that one alpha receptor controls and blocks the flow...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-10-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry